Artivion, Inc. (CRY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Artivion, Inc. (CRY) Healthcare & Pipeline Overview

Artivion, Inc. (CRY) develops, manufactures, and distributes medical devices and implantable tissues for cardiac and vascular surgery. With a focus on innovative solutions like BioGlue and On-X heart valves, Artivion serves physicians and hospitals globally, maintaining a significant presence in the medical device sector.

What Is the Investment Thesis for CRY?

Artivion Inc. presents a compelling investment case based on its established position in the medical device market and its focus on innovative solutions for cardiac and vascular diseases. With a market capitalization of $0.73 billion and a P/E ratio of 176.5, the company demonstrates growth potential. Key value drivers include continued adoption of its On-X heart valves and E-vita stent graft systems. Growth catalysts include expanding its product offerings and entering new geographic markets. However, investors should be aware of potential risks such as regulatory hurdles and competition from larger medical device companies. The company's gross margin of 63.8% indicates strong profitability, but its relatively low profit margin of 2.5% warrants monitoring.

Based on FMP financials and quantitative analysis

CRY Key Highlights

Market Cap of $0.73B reflects Artivion's valuation in the medical device market.

• P/E Ratio of 176.5 indicates investor expectations for future earnings growth.
• Gross Margin of 63.8% demonstrates strong pricing power and efficient cost management.
• Profit Margin of 2.5% suggests opportunities for improved operational efficiency and cost control.
• Beta of 1.53 indicates higher volatility compared to the overall market.

Who Are CRY's Competitors?

CRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRY's Key Strengths?

Innovative product portfolio with proprietary technologies.

• Established relationships with physicians and hospitals.
• Strong track record of regulatory approvals.
• Global distribution network.

What Are CRY's Weaknesses?

Relatively small market capitalization compared to major competitors.

• Low profit margin compared to industry peers.
• Dependence on a limited number of key products.
• High beta indicating higher volatility.

What Could Drive CRY Stock Higher?

Regulatory approvals for new products in key markets.

• Expansion of sales and marketing efforts in emerging markets.
• Continued adoption of On-X heart valves and E-vita stent graft systems.
• Publication of clinical data supporting the efficacy of Artivion's products.

What Are the Key Risks for CRY?

Rich valuation — a P/E of 176.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Product liability claims and recalls.
• Intense competition from larger medical device companies.
• Stringent regulatory requirements and potential delays in approvals.
• Economic downturns affecting healthcare spending.
• Fluctuations in currency exchange rates affecting international sales.

What Are the Growth Opportunities for CRY?

• Expansion of E-vita Stent Graft Systems: Artivion has the opportunity to further penetrate the aortic repair market with its E-vita stent graft systems. The global market for aortic repair devices is projected to reach $4 billion by 2028. By expanding its product offerings and distribution channels, Artivion can capture a larger share of this growing market. This includes focusing on minimally invasive procedures and customized solutions for complex aortic diseases.
• Increased Adoption of On-X Heart Valves: Artivion can drive growth through increased adoption of its On-X heart valves, known for their design and biocompatibility. The global heart valve market is estimated at $6 billion, with a steady growth rate. By highlighting the clinical benefits and long-term outcomes of On-X valves, Artivion can attract more surgeons and hospitals, leading to higher sales and market share.
• Geographic Expansion: Artivion has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing demand for advanced medical technologies. By establishing partnerships with local distributors and adapting its products to meet local needs, Artivion can tap into these high-growth markets and diversify its revenue streams.
• Strategic Acquisitions: Artivion can pursue strategic acquisitions to expand its product portfolio and enter new market segments. By acquiring companies with complementary technologies or established market positions, Artivion can accelerate its growth and enhance its competitive advantage. Potential acquisition targets could include companies specializing in vascular access devices, surgical instruments, or regenerative medicine.
• Development of Next-Generation Products: Artivion can invest in research and development to create next-generation medical devices and implantable tissues. This includes developing innovative solutions for unmet clinical needs, such as biodegradable implants, drug-eluting devices, and personalized medicine approaches. By staying at the forefront of technological innovation, Artivion can maintain its competitive edge and drive long-term growth.

What Are CRY's Competitive Advantages?

• Proprietary Technology: Artivion's BioGlue and On-X heart valves are protected by patents and trade secrets, providing a competitive advantage.
• Established Relationships: The company has long-standing relationships with physicians and hospitals, creating customer loyalty.
• Regulatory Expertise: Artivion has a strong track record of obtaining regulatory approvals for its products, demonstrating its expertise in navigating the complex regulatory landscape.
• Specialized Services: Artivion offers specialized services such as cardiac preservation and pyrolytic carbon coating, differentiating it from competitors.

What Does CRY Do?

Artivion Inc., formerly known as CryoLife, Inc., was founded in 1984 and is headquartered in Kennesaw, Georgia. The company rebranded as Artivion in January 2022 to reflect its expanded focus and innovative product portfolio. Artivion specializes in manufacturing, processing, and distributing medical devices and implantable human tissues, serving physicians, hospitals, and healthcare facilities worldwide. Its core products include BioGlue, a surgical adhesive used in cardiac, vascular, and pulmonary procedures; On-X prosthetic heart valves, known for their design and biocompatibility; and a range of stent graft systems under the E-vita brand, used for treating aortic diseases. Artivion also offers cardiac preservation services, bovine pericardial patches (PhotoFix), synthetic vascular grafts, and hemostatic products like PerClot. Additionally, the company provides specialized services such as pyrolytic carbon coating for other medical device manufacturers. Artivion's products are used by cardiac, vascular, thoracic, and general surgeons, establishing the company as a key player in the medical device industry with a global reach.

What Products and Services Does CRY Offer?

• Manufactures and distributes medical devices for cardiac and vascular surgery.
• Processes and sells implantable human tissues.
• Offers BioGlue, a surgical adhesive used in various surgical applications.
• Provides On-X prosthetic heart valves and aortic prostheses.
• Offers E-vita stent graft systems for aortic disease treatment.
• Sells PerClot, an absorbable hemostat for surgical procedures.
• Provides cardiac preservation services.
• Offers pyrolytic carbon coating services for medical devices.

How Does CRY Make Money?

• Artivion generates revenue through the sale of medical devices and implantable tissues.
• The company also earns revenue from cardiac preservation services and pyrolytic carbon coating services.
• Artivion distributes its products through a direct sales force and a network of distributors.
• The company focuses on serving physicians, hospitals, and healthcare facilities globally.

What Industry Does CRY Operate In?

Artivion operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory oversight. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population and increasing demand for advanced medical technologies. Artivion competes with larger medical device companies and specialized players in the cardiac and vascular segments. The company's focus on niche markets and innovative products, such as its On-X heart valves and E-vita stent graft systems, positions it favorably within this competitive landscape.

Who Are CRY's Key Customers?

• Cardiac surgeons
• Vascular surgeons
• Thoracic surgeons
• Hospitals and healthcare facilities
• General surgeons

Artivion, Inc. (CRY) Valuation Context

Relative to its peer group, CRY's quantitative score of 49/100 is below the peer average of 71/100.

Return on equity for Artivion, Inc. stands at 2.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.3%, showing how much profit it generates from its asset base. CRY trades at a trailing price-to-earnings ratio of 176.45, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.1%, the inverse of the P/E and a quick read on earnings relative to price.

CRY Financials

CRY Latest News

CRY Analyst Consensus

CRY MoonshotScore

CRY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources